Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719414 | 0.78 | POLB (0.39) | KMT2AMEN1HSD17B10KDM4EHPGD | |
| SCHEMBL6992442 | 0.75 | KMT2A (0.41) | NPSR1KMT2AMEN1HSD17B10KDM4E | |
| SCHEMBL1719664 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL6466595 | 0.70 | — | — | |
| SCHEMBL13751528 | 0.69 | TSHR (0.40) | GAANPSR1KMT2AMEN1HSD17B10 | |
| SCHEMBL2956715 | 0.67 | L3MBTL1 (0.40) | GAANPSR1KMT2AMEN1HSD17B10 | |
| SCHEMBL1719424 | 0.67 | ICAM1 (0.40) | GAAHSD17B10ALDH1A1L3MBTL1POLB | |
| SCHEMBL8938457 | 0.66 | LPO (0.48) | NPSR1KMT2AMEN1HSD17B10KDM4E | |
| SCHEMBL2661651 | 0.66 | GAA (0.41) | GAANPSR1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL9698982 | 0.66 | GAA (0.50) | GAAKMT2AMEN1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2013-10-17 | — | — | US | claimed |
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | claimed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | claimed |
| EP-2037928-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | Amgen Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | claimed |
| WO-2008002591-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2008-01-03 | — | — | WO | claimed |
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8426358-B2 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426358-B2 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426358-B2 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2037928-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | Amgen Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008002591-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | GAA 516/4885NPSR1 1282/4885KMT2A 2382/4885 |
| US-20080096900-A1 | Methods for treating atherosclerosis | LCAT, PCSK9, CETP | GAA 516/4885NPSR1 1282/4885KMT2A 2382/4885 |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | GAA 516/4885NPSR1 1282/4885KMT2A 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.